1 unchanged sentence
Trading Plans or Rule 10b5-1 Trading Plans
−Removed: During the quarter ended September 30, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.
+Added: During the quarter ended March 31, 2026, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.
Date of Adoption/
3 unchanged sentences
Non-Rule 10b5-1**
−Removed: Chief Operating and Financial Officer
−Removed: February 3, 2025
−Removed: Up to 150,000
−Removed: Chief Operating and Financial Officer
−Removed: Termination (3)
−Removed: September 10, 2025 (4)
+Added: Sean Bohen, M.D., Ph.D.
+Added: President and Chief Executive Officer
+Added: March 3, 2026
Up to 705,000
3 unchanged sentences
The number of shares to be sold was dependent on the satisfaction of certain conditions as set forth in the written plan.
−Removed: (1) We inadvertently omitted from Item 5 of Part II of our Quarterly Report on Form 10-Q for the quarterly period ending March 31, 2025, the disclosure of the adoption of a contract, instruction or written plan for the purchase or sale of our securities.
−Removed: (2) This plan was intended to qualify as a “Rule 10b5-1 trading arrangement” as defined in Item 408(a) of Regulation S-K.
−Removed: However, the plan did not comply with the cooling-off period required by Exchange Act Rule 10b5-1(c) and is therefore deemed a “Non-Rule 10b5-1 trading arrangement”.
−Removed: (3) This contract, instruction, or written plan was subsequently terminated on September 10, 2025, as disclosed above, prior to the completion of any sales under the plan.
−Removed: (4) Represents the termination of a written plan originally adopted on February 3, 2025 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Incorporated by Reference
1 unchanged sentence
Amended and Restated Bylaws.
−Removed: Certification of Chief Executive Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Chief Financial Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C.
+Added: Third Amendment to Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated January 11, 2026.
+Added: Separation and Consulting Agreement by and between the Company and Shane Kovacs.
+Added: Olema Pharmaceuticals, Inc.
+Added: Amended and Restated Non-Employee Director Compensation Policy.
+Added: Lease Agreement, dated April 27, 2026, between KR Oyster Point II, LLC and Olema Pharmaceuticals, Inc.
+Added: Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a‑14(a) and 15d‑14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C.
Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
3 unchanged sentences
* Filed herewith.
−Removed: The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, and are not to be incorporated by reference into any of the Registrant’s filings under the Securities Act, irrespective of any general incorporation language contained in any such filing.
+Added: The certifications attached as Exhibit 32.1 accompany this Quarterly Report pursuant to 18 U.S.C.
+Added: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, and are not to be incorporated
+Added: by reference into any of the Registrant’s filings under the Securities Act, irrespective of any general incorporation language contained in any such filing.
+Added: ¥ Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit have been omitted as the Registrant has determined that the omitted information is the type that the Registrant customarily and actually treats as private or confidential and is not material.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Olema Pharmaceuticals, Inc.
−Removed: November 10, 2025
/s/ Sean Bohen, M.D., Ph.D.
1 unchanged sentence
President and Chief Executive Officer
−Removed: ( Principal Executive Officer )
−Removed: November 10, 2025
−Removed: /s/ Shane Kovacs
−Removed: Chief Operating and Financial Officer
−Removed: ( Principal Financial Officer and Principal Accounting Officer )
+Added: ( Principal Executive Officer and Principal Financial Officer )
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.